ReviewCureus2025
Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric obesity is a public health problem with long-term repercussions, in which there is limited effectiveness of interventions such as lifestyle changes. This study evaluated the efficacy and safety of liraglutide in overweight/obese children and adolescents (six to 18 years) using a systematic review and meta-analysis of randomized clinical trials (RCTs). Databases such as PubMed, Web of Science, and ClinicalTrials.gov were searched up to February 2025, and the analysis included four RCTs (n=378). Liraglutide significantly reduced BMI Z-score (standardized mean difference or SMD: -1.03; 95% CI: -1.24 to -0.81; I²=0%) and showed modest improvements in HbA1c (SMD: -1.14; 95% CI: -2.10 to -0.17; I²=92%), though with high metabolic heterogeneity. There was a tendency toward increased hypoglycemia (relative risk or RR: 1.55; 95% CI: 1.00-2.40), but there was no significant difference in the overall adverse effects (RR: 1.06; 95% CI: 0.97-1.15). The results support the use of liraglutide to reduce BMI in this population, but the current evidence is limited by the small number of studies, methodological biases, and variability in metabolic outcomes. More robust RCTs and studies with prolonged follow-up are needed to consolidate liraglutide's role in the management of pediatric obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.